Expression data of multiple sclerosis patients receiving intramuscular Interferon-beta-1a therapy [U133 A and B]. Homo sapiens

The purpose of this study was to characterize the transcriptional effects induced by intramuscular IFN-beta-1a treatment (Avonex, 30 µg once weekly) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 24 MS patients within the first four weeks of IFN-beta administration. Keywords: Multiple sclerosis, Interferon, Pharmacogenomics, Affymetrix Overall design: EDTA blood samples were taken from all patients immediately before first, second and fifth IFN-beta injection. Total RNA of Ficoll-isolated peripheral blood mononuclear cells from each sample was extracted, labeled and hybridized to Affymetrix Human Genome U133 A and B arrays to quantify the mRNA levels.

本研究旨在表征复发缓解型多发性硬化（multiple sclerosis, MS）患者接受肌内注射干扰素β-1a（IFN-β-1a，商品名Avonex，每周一次30μg）所诱导的转录组学效应。本研究采用Affymetrix DNA微阵列技术，在24名多发性硬化患者接受IFN-β治疗的前四周内，获取了其外周血单个核细胞（peripheral blood mononuclear cells, PBMCs）的全基因组表达谱。
关键词：多发性硬化、干扰素、药物基因组学、Affymetrix
实验设计：所有患者均在首次、第二次及第五次IFN-β注射前即刻采集EDTA抗凝血样本。对每份样本中经Ficoll密度梯度离心分离得到的外周血单个核细胞提取总RNA，经标记后与Affymetrix人类基因组U133 A和B芯片杂交，以定量mRNA水平。